Exelixis and Catalent enter into collaboration, license, and exclusive option agreement to develop antibody-drug conjugates leveraging SMARTag® bioconjugation technology
Companies will partner to develop novel antibody-drug conjugates using Catalent’s SMARTag bioconjugation platform and monoclonal antibodies from Exelixis’ growing preclinical pipeline Agreement includes exclusive options on multiple targets over three-year term, with potential to extend time and scope of the collaboration Deal